Recent Finacing
Recent Raise
Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops rare disease drugs deprioritized by big pharma, with a lead program rugonersen for Angelman syndrome.
Focus Areas
Recent Investors
Total Raised
Funding round
See the team members at Oak Hill Bio.
